Marino V.
- Country
- Germany
- Department
- Department of Gastroenterology, Hepatology and Infectious Diseases (KGHI)
Research Overview
- Phase III Study of Rilvegostomig plus Combination Chemotherapy versus Durvalumab plus Combination Chemotherapy in Patients with Advanced Biliary Tract Cancer
- Efficacy and Safety of REGN7508 for Primary Prophylaxis of Cancer-Associated Thrombosis in Patients with Solid Tumors Undergoing Cancer Treatment
- Phase III Randomized Trial of AZD0901 with Capecitabine ± Rilvegostomig in First‑Line Claudin‑18.2‑Positive HER2‑Negative Advanced Gastric, GEJ or Esophageal Adenocarcinoma
Data & Insights
Has run more than one trial at 158 of 438 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in treating various forms of gastrointestinal cancers, with particular focus on esophagogastric adenocarcinoma and colorectal cancer.
- Advanced gastric cancer treatment
- Metastatic colorectal cancer management
- Gastrointestinal stromal tumors
Expertise includes innovative therapeutic approaches combining immunotherapy with conventional treatments for gastrointestinal malignancies.
Hepatobiliary Oncology
Demonstrates significant expertise in treating hepatocellular carcinoma and cholangiocarcinoma, employing various therapeutic strategies.
- Advanced liver cancer treatments
- Locoregional therapy approaches
- Biliary tract cancer management
Focuses on combining targeted therapies with immunotherapy for hepatobiliary cancers.
Pancreatic Cancer
Specializes in treating pancreatic ductal adenocarcinoma, with emphasis on advanced stage disease management.
- Metastatic pancreatic cancer treatment
- Novel combination therapies
- Chemotherapy optimization
Implements innovative therapeutic strategies for improving survival outcomes in pancreatic cancer patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.